Enterprise Value

200.9M

Cash

300.3M

Avg Qtr Burn

-26.83M

Short % of Float

18.06%

Insider Ownership

6.09%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MAVYRET (Glecaprevir) Details
HCV (Hepatitis C Virus)

Approved

Quarterly sales

Zelicapavir /EDP-938 (N protein-inhibitor) Details
Viral infection, Respiratory syncytial virus, Respiratory virus

Phase 2

Data readout

EDP-235 Details
Viral infection, COVID-19

Phase 2

Update

Phase 2

Initiation

EDP-323 Details
Respiratory virus, Viral infection, Respiratory syncytial virus

Phase 2a

Data readout

EDP-305 (FXR Agonist) Details
Non-alcoholic steatohepatitis

Failed

Discontinued

ENP-297 (FXR inhibitor) Details
Non-alcoholic steatohepatitis

Failed

Discontinued